Larry Luxner,  —

Articles by Larry Luxner

TV Personality Montel Williams Launches ‘My MS: Second Act’

A little over 20 years ago, Montel Williams learned once and for all that he had multiple sclerosis (MS). But that determination should have happened long before then, said the well-known TV personality ā€” whoā€™s made fighting the neurodegenerative disease his lifeā€™s mission. Williams, 63, was the star attraction…

Newly Published NMSS Study Confirms Nearly 1 Million Americans Have MS

Itā€™s finally official: Around 900,000 Americans and quite possibly more than that have multiple sclerosis (MS) ā€” easily double the long-accepted figure of 400,000. Since MS News Today first reportedĀ on this finding in November 2017, the National Multiple Sclerosis SocietyĀ (NMSS) study, which reached that conclusion, has…

Canada Trails US in Patient Access to Rare Disease Therapies, CORD President Says

Canadaā€™s healthcare system is excellent for people with common ailments like diabetes or high blood pressure, but itā€™s ā€œbasically failing the nearly three million Canadians with rare diseases.ā€ So says Durhane Wong-Rieger, president and CEO of the Canadian Organization for Rare DisordersĀ (CORD), a Toronto-based network representing 102 patient advocacy…

5 MS Patients Across US Talk About How Ocrevus Has Changed Their Lives

Itā€™s been a little over a year since U.S. regulators approved Genentechā€™sĀ Ocrevus (ocrelizumab)Ā as the first treatment for both relapsing and progressive forms of multiple sclerosis (MS) ā€” a disabling neurological diseaseĀ now believed to affect nearly one million Americans. While the juryā€™s still outĀ regarding the therapyā€™s…

Ocrevus a Year After Approval: Views of Some MS Experts

A year after U.S. regulators approved Genentech’sĀ Ocrevus (ocrelizumab)Ā as the first treatment for both the relapsing and progressive forms of multiple sclerosis, a prominent neurologist involved in the Phase 3 clinical trials that led to its authorization says it has been beneficial for some MS patients. But itā€™s simply…